10:31 AM EDT, 06/02/2025 (MT Newswires) -- Vera Therapeutics ( VERA ) shares climbed by nearly 60% in recent Monday trading after the biotechnology firm said a phase 3 trial of atacicept to treat immunoglobulin A nephropathy in adults achieved its primary endpoint.

The primary efficacy endpoint was the change in 24-hour urine protein-to-creatinine ratio versus placebo at the 36-week interim analysis, the company said.

The phase 3 trial of 431 patients achieved a 46% reduction from baseline in proteinuria as measured by 24-hour UPCR, as well as a "clinically meaningful" 42% drop in UPCR compared with placebo at week 36, according to a statement.

The safety profile was favorable and comparable to placebo, according to a company statement.

The company said it plans to meet with the US Food and Drug Administration in the coming weeks and discuss the regulatory pathway.

Price: 30.44, Change: +11.49, Percent Change: +60.63